Intervacc is trading 18.36% lower at €0.05, with broader biotech weakness likely contributing to the decline. - Shares fell from recent €0.07 closes; XBI was down 2.04% as elevated Treasury yields and renewed inflation concerns weakened risk appetite. - No credible company-specific announcement, earnings update, regulatory action, transaction, or analyst catalyst was identified for September 23–24, 2026. - The latest located company communication concerned participation in an October healthcare conference, not a negative development.